secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHINA PHARMA HOLDINGS, INC. (CPHI)
CIK:        0001106644
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001213900-24-040851
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 4.01
LLM model:  deepseek-v4-flash:cloud@v2

China Pharma terminates auditor BF Borgers after SEC denies its practice privilege; appoints Enrome LLP
--------------------------------------------------------------------------------

- SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
- China Pharma terminated Borgers as independent auditor on May 7, 2024, with audit committee approval.
- Audit committee engaged Enrome LLP as new independent registered public accounting firm, effective May 7, 2024.
- No disagreements or reportable events occurred with Borgers during the past two fiscal years through termination.
- Borgers' audit reports for FY2023 and FY2022 contained a going-concern qualification but no adverse opinion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1106644/000121390024040851/0001213900-24-040851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1106644/000121390024040851/ea0205550-8k_chinapharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-040851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer